Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Italy-based Health Robotics, a provider of robotic technology and software automation services, has signed a definitive agreement with the Devon International Group, or DIG, whereby DIG has acquired the exclusive rights to Health Robotics's CytoCare and iv Station robots in China.
Subscribe to our email newsletter
CytoCare is an automated robotic system for the safe preparation of hazardous patient-specific IV medications. Originally developed for cancer therapy, CytoCare has also been proven to compound monoclonal antibodies therapy IV admixtures to treat patients with Crohn’s disease, organ transplants, multiple sclerosis, rheumatoid arthritis, and infectious diseases, said Health Robotics.
DIG is expected to initially staff its Health Robotics product team at its Beijing and Shanghai office locations, in addition to planned local manufacturing operations.
John Bennett, CEO of Devon International Group, said: While CytoCare remedies the considerable Chinese-specific problem of retention of child-bearing-age clinicians due to the hazardous nature of chemo IVs, iv Station solves the IV sterility issues associated with compounding at non-sterile patient care locations.
We look forward to officially launch both Health Robotics’s solutions at the China International Medical Equipment Fair in Shenzhen on April 18-21, 2009.